%0 Journal Article
%A Mendonça-de-Pontes, Roberia
%A Flores-Montero, Juan
%A Sanoja-Flores, Luzalba
%A Puig, Noemi
%A Pessoa-de-Magalhães, Roberto J
%A Corral-Mateos, Alba
%A Salgado, Anna Beatriz
%A Garcia-Sanchez, Omar
%A Perez-Moran, Jose
%A Mateos, Maria-Victoria
%A Burgos, Leire
%A Paiva, Bruno
%A Te-Marvelde, Jeroen
%A van-der-Velden, Vincent H J
%A Aguilar, Carlos
%A Barez, Abelardo
%A Garcia-Mateo, Aranzazu
%A Labrador, Jorge
%A Leoz, Pilar
%A Aguilera-Sanz, Carmen
%A Durie, Brian
%A van-Dongen, Jacques J M
%A Maiolino, Angelo
%A Sobral-da-Costa, Elaine
%A Orfao, Alberto
%T B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients.
%D 2021
%@ 2072-6694
%U http://hdl.handle.net/10668/17662
%X B-cell regeneration during therapy has been considered as a strong prognostic factor in multiple myeloma (MM). However, the effects of therapy and hemodilution in bone marrow (BM) B-cell recovery have not been systematically evaluated during follow-up. MM (n = 177) and adult (≥50y) healthy donor (HD; n = 14) BM samples were studied by next-generation flow (NGF) to simultaneously assess measurable residual disease (MRD) and residual normal B-cell populations. BM hemodilution was detected in 41 out of 177 (23%) patient samples, leading to lower total B-cell, B-cell precursor (BCP) and normal plasma cell (nPC) counts. Among MM BM, decreased percentages (vs. HD) of BCP, transitional/naïve B-cell (TBC/NBC) and nPC populations were observed at diagnosis. BM BCP increased after induction therapy, whereas TBC/NBC counts remained abnormally low. At day+100 postautologous stem cell transplantation, a greater increase in BCP with recovered TBC/NBC cell numbers but persistently low memory B-cell and nPC counts were found. At the end of therapy, complete response (CR) BM samples showed higher CD19- nPC counts vs. non-CR specimens. MRD positivity was associated with higher BCP and nPC percentages. Hemodilution showed a negative impact on BM B-cell distribution. Different BM B-cell regeneration profiles are present in MM at diagnosis and after therapy with no significant association with patient outcome.
%K B-cell regeneration
%K hemodilution
%K immunophenotyping
%K measurable residual disease
%K multiple myeloma
%~